Aurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis
VICTORIA, British Columbia& ROCKVILLE, Md.--(BUSINESS WIRE) July 21, 2020 -- Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the“Company”), a late-stage clinical biopharmaceutical company focused on...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | Lupus | Nephritis | New Drug Applications | UK Health